Short Interest in Antares Pharma, Inc. (NASDAQ:ATRS) Expands By 86.2%

Antares Pharma, Inc. (NASDAQ:ATRSGet Rating) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 7,280,000 shares, a growth of 86.2% from the April 15th total of 3,910,000 shares. Approximately 4.4% of the company’s stock are short sold. Based on an average daily volume of 4,320,000 shares, the short-interest ratio is presently 1.7 days.

Several large investors have recently modified their holdings of ATRS. Stonepine Capital Management LLC increased its holdings in shares of Antares Pharma by 769.9% in the 4th quarter. Stonepine Capital Management LLC now owns 2,297,360 shares of the specialty pharmaceutical company’s stock valued at $8,202,000 after acquiring an additional 2,033,260 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Antares Pharma by 166.6% in the 1st quarter. Russell Investments Group Ltd. now owns 3,045,999 shares of the specialty pharmaceutical company’s stock valued at $12,487,000 after acquiring an additional 1,903,508 shares during the period. Rubric Capital Management LP increased its holdings in shares of Antares Pharma by 8.0% in the 4th quarter. Rubric Capital Management LP now owns 10,800,000 shares of the specialty pharmaceutical company’s stock valued at $38,556,000 after acquiring an additional 800,000 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Antares Pharma by 311.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,037,736 shares of the specialty pharmaceutical company’s stock valued at $4,255,000 after acquiring an additional 785,443 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Antares Pharma by 167.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,139,703 shares of the specialty pharmaceutical company’s stock valued at $4,069,000 after acquiring an additional 713,905 shares during the period. Institutional investors and hedge funds own 50.41% of the company’s stock.

A number of research analysts recently weighed in on ATRS shares. StockNews.com cut shares of Antares Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, April 20th. Raymond James downgraded shares of Antares Pharma from a “strong-buy” rating to a “market perform” rating in a research note on Thursday, April 14th. HC Wainwright downgraded shares of Antares Pharma from a “buy” rating to a “neutral” rating and set a $5.60 price target for the company. in a research note on Thursday, April 14th. Truist Financial downgraded shares of Antares Pharma from a “buy” rating to a “hold” rating and decreased their price target for the stock from $7.00 to $5.60 in a research note on Wednesday, April 13th. Finally, LADENBURG THALM/SH SH downgraded shares of Antares Pharma from a “buy” rating to a “neutral” rating in a research note on Thursday, April 14th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Antares Pharma currently has an average rating of “Hold” and an average price target of $5.76.

Shares of NASDAQ:ATRS opened at $5.57 on Friday. The company has a market capitalization of $951.26 million, a PE ratio of 20.63 and a beta of 1.15. The company has a current ratio of 2.96, a quick ratio of 2.76 and a debt-to-equity ratio of 0.10. Antares Pharma has a twelve month low of $3.11 and a twelve month high of $5.59. The firm has a 50 day simple moving average of $4.69 and a 200-day simple moving average of $3.91.

Antares Pharma (NASDAQ:ATRSGet Rating) last issued its quarterly earnings data on Thursday, March 3rd. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.01. The business had revenue of $48.73 million during the quarter, compared to the consensus estimate of $46.25 million. Antares Pharma had a net margin of 25.16% and a return on equity of 12.33%. During the same quarter in the previous year, the firm earned $0.03 EPS. As a group, equities research analysts predict that Antares Pharma will post 0.08 EPS for the current fiscal year.

About Antares Pharma (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

See Also

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.